Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Cash & Equivalents (2019 - 2025)

Cyclerion Therapeutics has reported Cash & Equivalents over the past 7 years, most recently at $4.6 million for Q3 2025.

  • Quarterly results put Cash & Equivalents at $4.6 million for Q3 2025, up 59.05% from a year ago — trailing twelve months through Sep 2025 was $4.6 million (up 59.05% YoY), and the annual figure for FY2024 was $3.2 million, down 57.31%.
  • Cash & Equivalents for Q3 2025 was $4.6 million at Cyclerion Therapeutics, up from $3.0 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for CYCN hit a ceiling of $70.4 million in Q2 2021 and a floor of $2.9 million in Q3 2024.
  • Median Cash & Equivalents over the past 5 years was $7.6 million (2023), compared with a mean of $20.6 million.
  • Biggest five-year swings in Cash & Equivalents: tumbled 82.57% in 2023 and later surged 59.05% in 2025.
  • Cyclerion Therapeutics' Cash & Equivalents stood at $54.0 million in 2021, then crashed by 75.2% to $13.4 million in 2022, then crashed by 43.42% to $7.6 million in 2023, then tumbled by 57.31% to $3.2 million in 2024, then soared by 41.34% to $4.6 million in 2025.
  • The last three reported values for Cash & Equivalents were $4.6 million (Q3 2025), $3.0 million (Q2 2025), and $3.6 million (Q1 2025) per Business Quant data.